Anchor Investment Management LLC Has $80,000 Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Anchor Investment Management LLC lowered its stake in United Therapeutics Co. (NASDAQ:UTHR) by 37.5% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 250 shares of the biotechnology company’s stock after selling 150 shares during the quarter. Anchor Investment Management LLC’s holdings in United Therapeutics were worth $80,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. ClariVest Asset Management LLC increased its position in shares of United Therapeutics by 120.0% during the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 42 shares during the last quarter. V Square Quantitative Management LLC bought a new position in shares of United Therapeutics in the second quarter valued at $30,000. Rise Advisors LLC acquired a new position in United Therapeutics during the first quarter worth $32,000. Innealta Capital LLC bought a new stake in United Therapeutics during the second quarter worth $33,000. Finally, Benjamin F. Edwards & Company Inc. lifted its stake in United Therapeutics by 63.6% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 117 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Trading Up 1.7 %

UTHR stock opened at $355.93 on Friday. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $366.08. The company has a market capitalization of $15.79 billion, a PE ratio of 16.83, a price-to-earnings-growth ratio of 1.28 and a beta of 0.57. The company’s 50-day simple moving average is $343.70 and its 200 day simple moving average is $298.52. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.18 and a current ratio of 4.35.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The business had revenue of $714.90 million for the quarter, compared to analyst estimates of $691.87 million. During the same quarter in the previous year, the company earned $5.24 EPS. The business’s revenue for the quarter was up 19.8% on a year-over-year basis. As a group, sell-side analysts anticipate that United Therapeutics Co. will post 24.71 earnings per share for the current year.

Insider Buying and Selling

In other United Therapeutics news, CFO James Edgemond sold 7,785 shares of United Therapeutics stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total value of $2,821,050.45. Following the completion of the transaction, the chief financial officer now directly owns 2,615 shares of the company’s stock, valued at $947,597.55. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CFO James Edgemond sold 7,785 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $362.37, for a total value of $2,821,050.45. Following the completion of the transaction, the chief financial officer now directly owns 2,615 shares in the company, valued at approximately $947,597.55. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 269 shares of the stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $348.41, for a total transaction of $93,722.29. Following the sale, the chief executive officer now owns 130 shares in the company, valued at $45,293.30. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 108,244 shares of company stock valued at $36,327,546 over the last 90 days. 12.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Wells Fargo & Company boosted their price objective on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 20th. Bank of America dropped their price objective on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a research note on Thursday, August 1st. HC Wainwright reiterated a “buy” rating and set a $400.00 target price on shares of United Therapeutics in a research note on Thursday, August 1st. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 2nd. Finally, TD Cowen lifted their price objective on shares of United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a research report on Thursday, July 11th. One research analyst has rated the stock with a sell rating, three have given a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $357.17.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.